| P2093 | author name string | X William Yang | |
| | Matthew B Veldman | |
| P2860 | cites work | Huntingtin interacting proteins are genetic modifiers of neurodegeneration | Q21145230 |
| | The choreography of neuroinflammation in Huntington's disease | Q26828403 |
| | Mutant huntingtin downregulates myelin regulatory factor-mediated myelin gene expression and affects mature oligodendrocytes | Q27305777 |
| | Impaired TrkB receptor signaling underlies corticostriatal dysfunction in Huntington's disease | Q29144918 |
| | The CB1 cannabinoid receptor signals striatal neuroprotection via a PI3K/Akt/mTORC1/BDNF pathway | Q29306901 |
| | A general framework for weighted gene co-expression network analysis | Q29617580 |
| | SorCS2-mediated NR2A trafficking regulates motor deficits in Huntington's disease | Q29994841 |
| | Proteomic analysis of wild-type and mutant huntingtin-associated proteins in mouse brains identifies unique interactions and involvement in protein synthesis | Q30418699 |
| | Synaptic mutant huntingtin inhibits synapsin-1 phosphorylation and causes neurological symptoms | Q30441124 |
| | The mouse cortico-striatal projectome | Q30489469 |
| | Expression of mutant huntingtin in mouse brain astrocytes causes age-dependent neurological symptoms | Q30492587 |
| | Neuronal targets for reducing mutant huntingtin expression to ameliorate disease in a mouse model of Huntington's disease | Q30581321 |
| | Genetic rescue of CB1 receptors on medium spiny neurons prevents loss of excitatory striatal synapses but not motor impairment in HD mice | Q30588621 |
| | Huntington disease: natural history, biomarkers and prospects for therapeutics | Q30774172 |
| | A restricted population of CB1 cannabinoid receptors with neuroprotective activity | Q33730578 |
| | Astrocyte Kir4.1 ion channel deficits contribute to neuronal dysfunction in Huntington's disease model mice | Q33781761 |
| | New insights on the role of microglia in synaptic pruning in health and disease | Q33821505 |
| | Mutant Huntingtin promotes autonomous microglia activation via myeloid lineage-determining factors | Q33959395 |
| | Early increase in extrasynaptic NMDA receptor signaling and expression contributes to phenotype onset in Huntington's disease mice | Q34098463 |
| | Synaptic versus extrasynaptic NMDA receptor signalling: implications for neurodegenerative disorders | Q34138025 |
| | Network organization of the huntingtin proteomic interactome in mammalian brain | Q34287971 |
| | BDNF overexpression in the forebrain rescues Huntington's disease phenotypes in YAC128 mice | Q34338809 |
| | Huntingtin-interacting protein 1 influences worm and mouse presynaptic function and protects Caenorhabditis elegans neurons against mutant polyglutamine toxicity. | Q34700142 |
| | Expression profiling of Huntington's disease models suggests that brain-derived neurotrophic factor depletion plays a major role in striatal degeneration | Q34706597 |
| | Balance between synaptic versus extrasynaptic NMDA receptor activity influences inclusions and neurotoxicity of mutant huntingtin | Q35013054 |
| | Functional Indicators of Glutamate Transport in Single Striatal Astrocytes and the Influence of Kir4.1 in Normal and Huntington Mice. | Q45294943 |
| | Pathological cell-cell interactions elicited by a neuropathogenic form of mutant Huntingtin contribute to cortical pathogenesis in HD mice. | Q45296827 |
| | Age-related axonal swellings precede other neuropathological hallmarks in a knock-in mouse model of Huntington's disease | Q45299632 |
| | Chronic cannabinoid receptor stimulation selectively prevents motor impairments in a mouse model of Huntington's disease | Q45301104 |
| | Integrated genomics and proteomics define huntingtin CAG length-dependent networks in mice. | Q46306829 |
| | Huntingtin-associated protein-1 is a synapsin I-binding protein regulating synaptic vesicle exocytosis and synapsin I trafficking. | Q48669214 |
| | Cortical efferents lacking mutant huntingtin improve striatal neuronal activity and behavior in a conditional mouse model of Huntington's disease | Q35164101 |
| | Systematic interaction network filtering identifies CRMP1 as a novel suppressor of huntingtin misfolding and neurotoxicity | Q35561965 |
| | Pathological cell-cell interactions are necessary for striatal pathogenesis in a conditional mouse model of Huntington's disease | Q35828444 |
| | Analysis of YFP(J16)-R6/2 reporter mice and postmortem brains reveals early pathology and increased vulnerability of callosal axons in Huntington's disease | Q35999314 |
| | Selective vulnerability of Rich Club brain regions is an organizational principle of structural connectivity loss in Huntington's disease | Q36206024 |
| | Systems biology and gene networks in neurodevelopmental and neurodegenerative disorders | Q36424672 |
| | Enhanced Store-Operated Calcium Entry Leads to Striatal Synaptic Loss in a Huntington's Disease Mouse Model. | Q36431970 |
| | Up-regulation of GLT1 expression increases glutamate uptake and attenuates the Huntington's disease phenotype in the R6/2 mouse | Q36713909 |
| | Dysfunctional Calcium and Glutamate Signaling in Striatal Astrocytes from Huntington's Disease Model Mice | Q36718633 |
| | Full-length human mutant huntingtin with a stable polyglutamine repeat can elicit progressive and selective neuropathogenesis in BACHD mice | Q37072467 |
| | Genetic manipulations of mutant huntingtin in mice: new insights into Huntington's disease pathogenesis | Q37165188 |
| | Loss of corticostriatal and thalamostriatal synaptic terminals precedes striatal projection neuron pathology in heterozygous Q140 Huntington's disease mice | Q37255018 |
| | TRiC subunits enhance BDNF axonal transport and rescue striatal atrophy in Huntington's disease | Q37281403 |
| | Neocortical expression of mutant huntingtin is not required for alterations in striatal gene expression or motor dysfunction in a transgenic mouse | Q37294750 |
| | A small molecule TrkB ligand reduces motor impairment and neuropathology in R6/2 and BACHD mouse models of Huntington's disease | Q37345118 |
| | Suppressing aberrant GluN3A expression rescues synaptic and behavioral impairments in Huntington's disease models | Q37607024 |
| | Neurotransmitter roles in synaptic modulation, plasticity and learning in the dorsal striatum | Q37680104 |
| | Huntington's disease: can mice lead the way to treatment? | Q37840353 |
| | Pathophysiology of Huntington's disease: time-dependent alterations in synaptic and receptor function. | Q37930190 |
| | Corticostriatal synaptic adaptations in Huntington's disease | Q38362877 |
| | Exosomes and Homeostatic Synaptic Plasticity Are Linked to Each other and to Huntington's, Parkinson's, and Other Neurodegenerative Diseases by Database-Enabled Analyses of Comprehensively Curated Datasets | Q38726920 |
| | Unravelling and Exploiting Astrocyte Dysfunction in Huntington's Disease. | Q38746156 |
| | The Biology of Huntingtin. | Q38759081 |
| | New coumarins from the roots of Angelica dahurica var. formosana cv. Chuanbaizhi and their inhibition on NO production in LPS-activated RAW264.7 cells | Q38913463 |
| | Mutant Huntingtin alters retrograde transport of TrkB receptors in striatal dendrites. | Q39168396 |
| | Widespread disruption of repressor element-1 silencing transcription factor/neuron-restrictive silencer factor occupancy at its target genes in Huntington's disease. | Q39333674 |
| | Reactive Astrocytes: Production, Function, and Therapeutic Potential | Q39388343 |
| | Disruption of Rab11 activity in a knock-in mouse model of Huntington's disease | Q39809646 |
| | Rab11 rescues synaptic dysfunction and behavioural deficits in a Drosophila model of Huntington's disease | Q42098044 |
| | Genetically-directed Sparse Neuronal Labeling in BAC Transgenic Mice through Mononucleotide Repeat Frameshift | Q42121380 |
| | Endocannabinoid-mediated rescue of striatal LTD and motor deficits in Parkinson's disease models | Q42508054 |
| | Mutant huntingtin's effects on striatal gene expression in mice recapitulate changes observed in human Huntington's disease brain and do not differ with mutant huntingtin length or wild-type huntingtin dosage | Q42512972 |
| | Dendritic spine loss and neurodegeneration is rescued by Rab11 in models of Huntington's disease | Q42790645 |
| | Peroxisome-proliferator-activated receptor gamma coactivator 1 α contributes to dysmyelination in experimental models of Huntington's disease | Q42792348 |
| | Decreased neuronal and increased oligodendroglial densities in Huntington's disease caudate nucleus | Q43814253 |
| | Abnormal association of mutant huntingtin with synaptic vesicles inhibits glutamate release | Q44545687 |
| | In vivo delivery of DN:REST improves transcriptional changes of REST-regulated genes in HD mice | Q45290714 |
| | Early striatal dendrite deficits followed by neuron loss with advanced age in the absence of anterograde cortical brain-derived neurotrophic factor. | Q45293425 |
| P921 | main subject | Huntington's disease | Q190564 |
| | striatum | Q1319792 |
| P304 | page(s) | 79-89 | |
| P577 | publication date | 2017-11-07 | |
| P1433 | published in | Current Opinion in Neurobiology | Q15763572 |
| P1476 | title | Molecular insights into cortico-striatal miscommunications in Huntington's disease | |
| P478 | volume | 48 | |